Pharmaceutical industry – Page 30
-
BusinessEU recommends withdrawing drugs approved on unreliable data
Indian firm Micro Therapeutic Research Labs accused of misrepresenting clinical data and documentation deficiencies
-
BusinessIndian drug industry opposes price caps
Government wants free healthcare for poorest people, but companies claim controls will stifle innovation
-
BusinessExpanding precision medicine beyond cancer
Exclusive interview with Koustubh Ranade, vice president of R&D at MedImmune
-
OpinionHow does being a chemist change your view on the world?
Scientific knowledge and analysis shape our view, but can also be selectively ignored
-
WhitepaperAnalytical method transfer
Learn about current best practice in a critical field for the industry
-
BusinessJ&J to close Scottish medical device plant
Up to 400 positions affected as Ethicon subsidiary leaves Livingston
-
FeatureHow ketamine could help treat severe depression
Nina Notman looks at how the party drug ketamine may hold the key to treating patients with severe depression
-
OpinionOutlines of ignorance
There’s a lot about chemistry that we just don’t understand very well yet
-
OpinionCollaboration and competition can both stimulate innovation
Diverse approaches suit different goals
-
BusinessCrispr patent ruling breaks deadlock
Both sides claim victory as board rules patents do not interfere with each other
-
Business$2bn Immunomedics–Seattle Genetics deal delayed amid shareholder infighting
Major investor venBio seeks to derail deal and replace board members
-
FeatureDeal or no deal?
Clare Sansom highlights recent changes in the landscape of pharma company collaborations and acquisitions
-
BusinessUniversity–industry collaborations aspire to pharmaceutical innovation
Three new UK partnerships illustrate drug research co-operation approaches that are growing in popularity
-
BusinessAllergan to buy fat-freezing firm Zeltiq
$2.5bn deal adds to firm’s cosmetic and aesthetic treatments
-
BusinessDaiichi Sankyo to close R&D sites in India and Japan
Closures are part of an ongoing reorganisation aimed at increasing productivity
-
BusinessUS biotech leaders protest immigration ban
Donald Trump’s suspended order would endanger America’s biotech industry if re-instated
-
BusinessLilly buys CoLucid for migraine drugs
US firm also laying off 485 sales staff after Alzheimer’s drug failure
-
BusinessMerck & Co settles cancer antibody patent dispute
US firm will pay Bristol-Myers Squibb and Ono $625m plus royalties on future sales of immunotherapy
-
BusinessTeva hit with fines and patent loss
Double whammy as firm settles subsidiary pay-for-delay suit and courts invalidate patents on multiple sclerosis drug
-
BusinessJ&J to buy Actelion for $30bn
Actelion’s R&D will spin out as a new company, while Janssen will take on in-market and late-stage medicines